News | February 03, 2014

Researcher Finds Significant Cardiac Treatment Imbalance Nationally

February 3, 2014 — Percutaneous coronary intervention (PCI) centers are unequal relative to population and heart attack prevalence across the United States, according to a study in the Journal of the American Heart Association. A multi-center team led by James Langabeer II, Ph.D., The University of Texas Health Science Center at Houston, conducted the study
 
Langabeer and co-lead author Timothy Henry, M.D., Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, found that people who live in urban areas have access to more PCI centers than necessary. Those who live in some rural areas are unable to access a PCI center within 60 minutes, the recommended time to receive treatment after the onset of heart attack symptoms.
 
Researchers examined the distribution of PCI centers in each state and compared that to population density and heart attack prevalence. The number of PCI centers has grown 21 percent nationwide in the last eight years, with 39 percent of all hospitals having interventional cardiology capabilities. While PCI centers continue to grow, heart attacks are decreasing. Langabeer’s discovery unveils an unequal geographic distribution of PCI capacity for treating heart attack patients.
 
Some western states, such as Nevada, had higher than median disease prevalence rates, yet have only an average number of PCI centers for its population. Locations in the south central and north central region, such as Alabama and Montana, had significantly higher relative PCI facilities compared to some of the states with even higher disease rates.
 
“There is a growing trend nationally for hospitals to all become PCI capable, for a variety of reasons. As long as the capacity is aligned with the need, this is positive. However, in this research, we found significant disparity geographically when we normalized capacity by population density” Langabeer said. “These imbalances are creating problems on a national scale.”
 
The study is called "Growth in Percutaneous Coronary Intervention Capacity Relative to Population and Disease Prevalence." Co-authors are from the American Heart Association, Boston University School of Medicine, Duke University Medical Center, The Christ Hospital Heart and Vascular Center and UT Southwestern Medical Center.
 
For more information: www.ahajournals.org

Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now